N-叔丁基-2-氯-N-甲基乙酰胺 | 158890-31-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-叔丁基-2-氯-N-甲基乙酰胺
• 英文名称: N-methyl-N-tert-butylchloroacetamide
• 英文别名: 2-chloro-N-methyl-N-tert-butyl acetamide；2-chloro-N-t-butyl-N-methylacetamide；N-tert-butyl-2-chloro-N-methylacetamide
• CAS: 158890-31-4
• 化学式: C₇H₁₄ClNO
• mdl: MFCD16301110
• 分子量: 163.647
• InChiKey: PMWFASNWZJXHIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-叔丁基-2-氯-N-甲基乙酰胺 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 3.0h， 生成 N-methyl-N-tert-butyliodoacetamide
  参考文献：
  名称：

  5-Phenyl-3-ureidobenzazepin-2-ones作为胆囊收缩素-B受体拮抗剂。

  摘要：

  使用合适的4-苯基-1-四氢萘酮的贝克曼环扩展作为关键步骤，合成了一系列5-苯基-3-脲基苯并ze庚因-2-酮胆囊收缩素-B（CCK-B）受体拮抗剂。结构-活性关系研究揭示了5-苯基对于有效和选择性CCK-B亲和力的重要性。添加8-甲基取代基和拆分提供了有效的（CCK-B IC50 = 0.48 nM）CCK-B拮抗剂4。5-苯基作为高亲和力受体拮抗作用的“特权结构”的一部分的作用是讨论过。

  DOI：

  10.1021/jm00048a015
• 作为产物：
  描述：

  N-甲基-叔丁基胺 、 氯乙酰氯 以 乙酸乙酯 为溶剂， 生成 N-叔丁基-2-氯-N-甲基乙酰胺
  参考文献：
  名称：

  5-Phenyl-3-ureidobenzazepin-2-ones作为胆囊收缩素-B受体拮抗剂。

  摘要：

  使用合适的4-苯基-1-四氢萘酮的贝克曼环扩展作为关键步骤，合成了一系列5-苯基-3-脲基苯并ze庚因-2-酮胆囊收缩素-B（CCK-B）受体拮抗剂。结构-活性关系研究揭示了5-苯基对于有效和选择性CCK-B亲和力的重要性。添加8-甲基取代基和拆分提供了有效的（CCK-B IC50 = 0.48 nM）CCK-B拮抗剂4。5-苯基作为高亲和力受体拮抗作用的“特权结构”的一部分的作用是讨论过。

  DOI：

  10.1021/jm00048a015

文献信息

• [EN] OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS OXADIAZOLE DE PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012040137A1

  公开（公告）日：2012-03-29

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药用盐，其中R1-R5如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• New D-proline prodrugs
  申请人：——

  公开号：US20030134891A1

  公开（公告）日：2003-07-17

  The invention relates to compounds of formulas 1 wherein R 1 and R 2 are independently from each other lower alkoxy, lower alkenyloxy, benzyloxy, hydroxy, —OCH(CH 3 )OC(O)-lower alkyl or —OCH 2 C(O)N(R 3 )(R 4 ), with the proviso that only one of R 1 or R 2 maybe hydroxy; R 3 and R 4 are independently from each other and signify hydrogen, lower alkyl, lower alkenyl or cycloalkyl; or R 1 and R 2 form together with the carbon atom, to which they are attached the linking group X, wherein X is —O(CH 2 ) n CH═CH(CH 2 ) n O— or —O(CH 2 ) m O—; n is 1, 2 or 3; and m is 4-8, or a pharmaceutically acceptable salt of said compound. Compounds of the present invention can be used for the treatment of diseases where Serum Amyloid P Component depletion has a beneficial effect, in particular in the treatment or prevention of central and systemic amyloidosis.

  该发明涉及以下公式的化合物： 其中R1和R2分别独立于彼此，为较低的烷氧基、较低的烯氧基、苄氧基、羟基、—OCH(CH3)OC(O)-较低烷基或—O C(O)N(R3)(R4)，但R1或R2中只有一个可能是羟基；R3和R4独立于彼此，表示氢、较低烷基、较低烯基或环烷基；或R1和R2与它们连接的碳原子一起形成连接基X，其中X为—O(CH2)nCH═CH( )nO—或—O( )mO—；n为1、2或3；m为4-8；或者所述化合物的药学上可接受的盐。 本发明的化合物可用于治疗血清淀粉样蛋白P成分耗竭对某些疾病具有有益作用的情况，特别是在治疗或预防中枢和全身淀粉样变性病方面。
• Selective Estrogen Receptor Modulator
  申请人：Hamaoka Shinichi

  公开号：US20120004315A1

  公开（公告）日：2012-01-05

  The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

  本发明提供一种由以下式（I）表示的化合物; [其中T表示单键，可能具有取代基的C1-C4烷基和类似物；式（I-1）表示单键或双键；A表示单键，可能具有取代基的双价5-至14-成员杂环基和类似物；Y表示单键和类似物；Z表示亚甲基基团和类似物；环G表示苯基团和类似物，可能与5-至6-成员环缩合并可能具有杂原子；Ra和Rb相同或不同，表示氢原子和类似物；W表示单键和类似物；R'表示1到4个独立的氢原子和类似物；R''表示1到4个独立的氢原子和类似物]或其盐或水合物。
• Selective estrogen receptor modulator
  申请人：Hamaoka Shinichi

  公开号：US20060116364A1

  公开（公告）日：2006-06-01

  The present invention provides a compound represented by the following formula [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof

  本发明提供了一种化合物，其表示为以下式子[其中T表示单键，C1-C4的烷基，可能带有取代基等；式(I-1)表示单键或双键；A表示单键，二价的5-至14-成员杂环基团，可能带有取代基等；Y表示单键等；Z表示亚甲基等；环G表示苯基团等，可与5-至6-成员环缩合并且可能具有杂原子；Ra和Rb相同或不同，表示氢原子等；W表示单键等；R'表示1至4个独立的氢原子等；R"表示1至4个独立的氢原子等]或其盐，或其水合物。
• SELECTIVE ESTROGEN RECEPTOR MODULATOR
  申请人：Hamaoka Shinichi

  公开号：US20090325930A1

  公开（公告）日：2009-12-31

  The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; (I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a and R b are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

  本发明提供了一种由以下式（I）表示的化合物；[其中，T表示单键，C1-C4烷基，可以有取代基等；（I-1）式（I-1）表示单键或双键；A表示单键，双价的5-至14-成员杂环基，可以有取代基等；Y表示单键等；Z表示亚甲基等；环G表示苯基等，可以与5-至6-成员环缩合，可以有杂原子；Ra和Rb相同或不同，表示氢原子等；W表示单键等；R′表示1至4个独立的氢原子等；R″表示1至4个独立的氢原子等]或其盐，或其水合物。